Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 10/20 | 0.76 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | BRD2 | P25440 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1438015 | 0.86 | MDM2 (1.00) | MDM2NR1H4CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1437548 | 0.85 | MDM2 (0.69) | MDM2NR1H4CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL27862793 | 0.85 | MDM2 (0.69) | MDM2NR1H4CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1437495 | 0.84 | MDM2 (0.65) | MDM2NR1H4CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1437322 | 0.84 | MDM2 (0.62) | MDM2NR1H4CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1438373 | 0.82 | MDM2 (0.62) | MDM2NR1H4CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL27862898 | 0.82 | MDM2 (0.62) | MDM2NR1H4CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL28796361 | 0.81 | MDM2 (0.60) | MDM2NR1H4CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL28796362 | 0.81 | MDM2 (0.60) | MDM2NR1H4CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1436783 | 0.80 | MDM2 (0.63) | MDM2NR1H4CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102574785-A | Tetra-substituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators | NOVARTIS AG | 2012-07-11 | — | — | CN | disclosed |
| EP-2470502-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | Novartis AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
| WO-2011023677-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885NR1H4 665/4885CYP3A4 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.